Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders) - Volume 21, Issue 7, 2021

Background: Functional imaging with ⁶⁸Ga-DOTATATE PET-CT is widely employed to detect both primary and metastatic pheochromocytomas and paragangliomas (PGL), but its results may be occasionally misleading as in the case here reported. Case Presentation: We report here a 75-year-old woman with an interaortocaval PGL that was diagnosed after a hypertensive crisis occurring during the resection of a kidney tumor. ⁶⁸Ga-DOTATATE PET-CT disclosed pathologic uptake in the abdomen and at the iliac crest. After the resection of the abdominal tumor, with the histological confirmation of PGL, arterial blood pressure and metanephrine levels were normalized. Genetic testing was negative. Thereafter, the bone lesion increased in size and became painful, requiring multiple medications. A selective biopsy disclosed a metastatic lesion arising from the renal tumor. Conclusion: The false-positive result of ⁶⁸Ga-DOTATATE PET-CT is discussed.

Background: Dysbiosis is related to changes in the composition and behaviour of intestinal microbiota, which may contribute to an age-related decline in metabolic and immune system functioning (immune-senescence). Objective: The microbiota-targeted dietary and probiotic interventions have been shown to favorably affect the host health by an enhancement of antioxidant activity, improving immune homeostasis, suppression of chronic inflammation, regulation of metabolism and prevention of insulin resistance. Results: In our study, the use of specific probiotics strains improved the serum concentration of glycemic markers, thereby promoting better overall health. Conclusion: Probiotics may help correct defects in the gut microbial environment improving metabolic parameters, such as blood sugar levels, glycosylated hemoglobin and a decrease in body weight.

Objective: To evaluate the efficacy and treatment satisfaction of dapagliflozin and liraglutide in T2DM patients with glucose poorly controlled after triple therapy. Methods: In addition to the original therapeutic regimen, dapagliflozin (n=83) and liraglutide (n=89) once a day were added, respectively. Height, body weight, waist circumference, and blood pressure were recorded. FBG, 2hPBG, HbA1c, fasting C-peptide, HOMA-IR, blood lipid, eGFR, BUA and DTSQ were detected before the treatment and after 24 weeks of treatment. Results: At the end of 24 weeks of treatment, a follow-up visit was completed for 79 patients in the dapagliflozin group and 77 patients in the liraglutide group. The body weight of the patients in the dapagliflozin group and the liraglutide group decreased significantly (P<0.05). The HbA1c level in the dapagliflozin group decreased from 8.96 ± 1.23% to 7.03 ±0.74% (P< 0.01), more than that in the liraglutide group, namely, from 8.99 ± 1.34% to 7.24 ±0.77% (P< 0.01). After 12 weeks of treatment, eGFR in the dapagliflozin group first decreased and then increased after 12 weeks of treatment. The percentages of patients achieving combined endpoints in the two groups were of no statistical significance (P=0.204). And there were mild adverse events in both groups. Conclusion: The add-on treatment of dapagliflozin and liraglutide had promising clinical outcomes in patients with T2DM and poorly controlled glucose after triple therapy, which include the improvement in blood glucose, insulin resistance, SBP, and renal function. However, the overall treatment satisfaction was higher in the dapagliflozin group.

Due to oversight on the part of the authors, the names of two of the co-authors have been incorrectly published in the article entitled, “Association between ABCC8 Ala1369Ser Polymorphism (rs757110 T/G) and Type 2 Diabetes Risk in an Iranian Population: A Case-Control Study”, 2021, Vol. 21, No. 3, pp. 441-447 [1]. The original article can be found online at: https://doi.org/10.2174/1871530320666200713091827. Original: Amin Bakhtiyari, Karimeh Haghani, Salar Bakhtiyari*, Mohammad A. Zaimy, Nooriali Zahed, Ali Gheysarzadeh, Shahram Darabi, Seidali Nahalkhani, Mansour Amraei and Iraj Alipourfard Corrected: Amin Bakhtiyari, Karimeh Haghani, Salar Bakhtiyari*, Mohammad A. Zaimy, Ali Noori-Zadeh, Ali Gheysarzadeh, Shahram Darabi, Ali Seidkhani-Nahal, Mansour Amraei and Iraj Alipourfard